Eva Jack | CBO |
Anna Protopapas | CEO |
Tim Lowinger | CSO |
David Spellman | CFO |
Boris Peaker | Cowen |
Jonathan Chang | Leerink Partners |
David Nierengarten | Wedbush Securities |
Jessica Fye | JPMorgan |
Good morning and welcome to the Mersana Therapeutics’ Fourth Quarter and Full Year 2017 conference call. Currently, all participants are in a listen-only mode. There will be a question-and-answer session at the end of this call. I would now like to turn the call to Mersana team. Please proceed.